Mar 29 2021Helius Medical Technologies (Canada) Join Forces With Brainfx to Create Educational Awareness on Innovative Treatment and Assessments in Brain HealthOct 28 2020Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain InjurySep 08 2020
In the News
As Seen On ...
PoNS™ is an authorized medical device and commercially available in Canada. PoNS™ is an investigational device in the EU and Australia and is currently under review for market clearance by the AUS TGA; PoNS™ is not commercially available in the US, EU, or Australia.
The device is intended for use as a short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The device is intended for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy.